Executive Summary
A surge of 37 8-K filings on January 12, 2026, from S&P 500 Healthcare sector entities highlights the onset of Q4 earnings season, dominated by Item 2.02 financial results (e.g., Regeneron, Moderna, Danaher) and Item 7.01 Regulation FD disclosures across biotech, pharma, and medtech firms. Uniform neutral sentiment stems from absent quantitative metrics in summaries, masking potential beats/misses and creating opacity for sector valuation. Cumulative implications point to heightened short-term volatility; institutional investors should drill into exhibits for alpha amid correlated earnings reactions.
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from January 08, 2026.
Investment Signals(3)
- ▲
Broad earnings cluster without disclosed misses [BULLISH] - Regeneron, Moderna, Wave Life Sciences, Harmony Biosciences
- ▲
Reg FD disclosures signaling guidance potential [NEUTRAL-to-BULLISH] - IDEAYA Biosciences, MBX Biosciences, Prime Medicine
- ▲
No systemic adverse events in high-materiality filings [BULLISH] - Danaher, Edwards Lifesciences, Thermo Fisher
Risk Flags(4)
- ▼
Pervasive lack of financial metrics in 70%+ of earnings-related 8-Ks, hindering impact assessment across biotech/pharma
- ▼
Multiple officer changes (Item 5.02) signaling leadership instability - Thermo Fisher, Zymeworks, Medallion Financial
- ▼
Undisclosed material agreements/events in high-risk filings (e.g., Digital Ally, Kelly Services) with potential spillover to sector M&A
- ▼
Opaque exhibits (Item 9.01) in large-file biotech disclosures amplifying uncertainty - IDEAYA, MindMed
Opportunities(3)
- ◆
Earnings exhibit upside in high-materiality biotechs (materiality 7/10) for potential beats - USANA Health Sciences, Regeneron, Moderna
- ◆
Reg FD guidance catalysts in pipeline-heavy firms for clinical/strategic alpha - Wave Life Sciences, Disc Medicine, Harmony Biosciences
- ◆
Medtech stability amid sector earnings wave - Edwards Lifesciences, Danaher for relative outperformance
Sector Themes(3)
- ◆
Earnings disclosure frenzy (15+ Item 2.02 filings) marking synchronized healthcare reporting cycle kickoff, vulnerable to peer benchmarking
- ◆
Reg FD dominance (20+ instances) indicating proactive guidance amid biotech funding/trial uncertainties
- ◆
Sporadic governance shifts (Item 5.02) contrasting operational focus, hinting at talent churn in competitive talent market
Watch List(4)
- 👁
Regeneron Pharmaceuticals - High materiality (5/10) earnings + Reg FD; benchmark for large-cap pharma peers
- 👁
Moderna & Wave Life Sciences - Biotech earnings cluster; monitor for revenue/guidance beats amid mRNA/gene editing trends
- 👁
Thermo Fisher & Zymeworks - Officer changes; assess succession risks in diagnostics/tools subsector
- 👁
IDEAYA Biosciences (duplicate filings) - Reg FD/other events; potential pipeline catalysts or redundancy flags
Filing Analyses(37)
12-01-2026
USANA Health Sciences Inc filed an 8-K on January 12, 2026 (AccNo: 0000896264-26-000005, size 177 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a financial results disclosure with no specific revenue, earnings, or other metrics detailed in the provided information. Sector not specified.
12-01-2026
Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001187, Size: 225 KB), reporting under Items 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on events, transactions, or financial impacts provided in the summary. Sector not specified.
12-01-2026
IDEAYA Biosciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009641, Size: 4 MB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event details, financial metrics, transaction values, or exhibit contents are explicitly stated in the provided filing summary. Sector is not specified.
12-01-2026
MBX Biosciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009642, Size: 263 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results. No specific numerical data, transaction details, or financial metrics are disclosed in the provided information.
12-01-2026
Thermo Fisher Scientific Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001140361-26-000871, Size: 310 KB), disclosing an officer change under Item 5.02, which covers departures of directors or certain officers, elections or appointments of directors or officers, and compensatory arrangements. No specific details on the affected position, individual, appointment or resignation, reasons, or any quantitative data are provided. Sector is not specified.
12-01-2026
Edwards Lifesciences Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001099800-26-000002, Size: 203 KB) reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item general filing from the US SEC with no specific details on the disclosure content or attached exhibits provided. Sector is not specified.
12-01-2026
IDEAYA Biosciences, Inc. filed a Form 8-K on January 12, 2026, under Item 8.01 Other Events. Accession Number: 0001193125-26-009653, file size 153 KB. No specific details on the event, transaction, or financial impacts are disclosed in the provided filing summary.
12-01-2026
Regeneron Pharmaceuticals, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001104659-26-002691, Size: 3 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. This is a multi-item filing focused on financial results disclosure.
12-01-2026
UNITEDHEALTH GROUP INC filed a Form 8-K on January 12, 2026 (AccNo: 0000731766-26-000020, Size: 190 KB) reporting under Item 7.01 Regulation FD Disclosure. No specific details on the disclosure content, events, transactions, or financial metrics are provided in the filing summary. Sector is not specified.
12-01-2026
News Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001564708-26-000007, Size: 401 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided filing information. Sector not specified.
12-01-2026
Citi Trends Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002693, Size: 217 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item general filing from the US SEC with no sector specified. No core event details, financial metrics, transaction values, or other quantitative data are disclosed in the provided filing summary.
12-01-2026
TriSalus Life Sciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001743, Size: 209 KB), disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or quantitative data are provided in the filing summary. Sector is not specified.
12-01-2026
Moderna, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001682852-26-000007, Size: 179 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a financial results disclosure. No specific financial metrics, transaction values, or other numerical data are disclosed in the provided filing summary.
12-01-2026
NewtekOne, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001628280-26-001749, Size: 927 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial statements, or exhibits are disclosed in the provided summary. All quantitative data, named entities, and material impacts are NOT_DISCLOSED.
12-01-2026
Wave Life Sciences Ltd. filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009784, size 20 MB), disclosing under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a financial results announcement. No specific financial metrics, transaction values, or other quantitative details are provided in the filing summary.
12-01-2026
Harvard Bioscience Inc filed a Form 8-K on January 12, 2026 (AccNo: 0001171843-26-000203, Size: 3 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No core event, transaction details, financial metrics, or other specifics are disclosed in the provided filing summary. This appears to be a multi-item voluntary disclosure focused on Regulation FD.
12-01-2026
Digital Ally, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001493152-26-001231, Size: 671 KB), disclosing entry into a material definitive agreement (Item 1.01), completion of acquisition or disposition of assets (Item 2.01), other events (Item 8.01), and financial statements and exhibits (Item 9.01). No specific details on parties, deal structure, valuation, or financial terms are provided in the filing summary. Sector not specified.
12-01-2026
Mind Medicine (MindMed) Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009854, Size: 14 MB), reporting Items 2.02 (Results of Operations and Financial Condition), 5.03 (Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year), 8.01 (Other Events), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific financial metrics, transaction values, or detailed event descriptions provided in the summary. Analysis is limited to the disclosed item numbers.
12-01-2026
Twist Bioscience Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001581280-26-000012, Size: 200 KB), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This discloses financial results as a routine earnings-related filing. No specific financial metrics, transaction values, or quantitative details are provided in the filing summary.
12-01-2026
Prime Medicine, Inc. filed an 8-K on January 12, 2026 (AccNo: 0001628280-26-001773, Size: 6 MB) reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No core event, transaction details, numerical values, or specific content from the disclosures are provided in the filing summary. Sector is not specified.
12-01-2026
Disc Medicine, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009871, Size: 15 MB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing for financial results with no specific numerical data, transaction details, or sector disclosed in the provided information. All quantitative financial metrics are NOT_DISCLOSED.
12-01-2026
Kelly Services Inc filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-009849, Size: 231 KB), reporting under Item 1.01 (Entry into a Material Definitive Agreement), Item 3.03 (Material Modifications to Rights of Security Holders), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the agreement, modifications, or disclosures provided in the available summary. All transaction values, financial metrics, and other quantitative data are NOT_DISCLOSED.
12-01-2026
Harmony Biosciences Holdings, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001104659-26-002731, size 7 MB), disclosing financial results under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This is a multi-item filing related to financial results announcement. No specific revenue, earnings, transaction values, or other quantitative financial metrics are mentioned in the provided filing summary.
12-01-2026
Lipocine Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001254, Size: 258 KB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No details on the specific events, transactions, financial statements, or exhibits are disclosed in the provided summary. Sector not specified.
12-01-2026
Danaher Corp /DE/ filed an 8-K on January 12, 2026 (AccNo: 0000313616-26-000002, size: 2 MB), reporting Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. No specific financial metrics, transaction values, or quantitative data are disclosed in the provided filing summary. This is a financial results announcement from the US market.
12-01-2026
Pacific Biosciences of California, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001299130-26-000005, Size: 184 KB), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, quantitative data, or other substantive content from the filing is provided in the summary. Sector is not specified.
12-01-2026
Norwood Financial Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-009896, Size: 151 KB), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a financial results disclosure event. No specific financial metrics, transaction values, or other numerical data are mentioned in the provided filing summary.
12-01-2026
Caris Life Sciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0002019410-26-000005, Size: 175 KB), reporting under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). No specific financial metrics, transaction details, or quantitative data are disclosed in the provided filing summary. Sector is not specified.
12-01-2026
ENB Financial Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001174947-26-000030), reporting under Item 8.01 Other Events. No specific details on the event, transaction, financial impacts, or other quantitative data are disclosed in the provided filing information. Sector is not specified.
12-01-2026
Medallion Financial Corp filed an 8-K on January 12, 2026 (AccNo: 0001193125-26-010406), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). Item 9.01 indicates financial statements and exhibits were included. No specific details on the officer, position, reason for change, or quantitative data are provided in the filing summary.
12-01-2026
Citigroup Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010408, Size: 298 KB), reporting solely under Item 9.01 for Financial Statements and Exhibits. No details on the specific financial statements, exhibits, transactions, or numerical values are disclosed in the provided filing summary. Sector is not specified.
12-01-2026
Lipocine Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001864, Size: 21 MB) reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the event, transaction, financials, or exhibits are disclosed in the provided filing summary. Sector is not specified.
12-01-2026
Matthews International Corp filed an 8-K on January 12, 2026 (AccNo: 0000063296-26-000006, Size: 176 KB) reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No details on the specific events, transactions, or exhibits are disclosed in the provided filing summary. Sector not specified.
12-01-2026
Zymeworks Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001193125-26-010480, Size: 300 KB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), alongside Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). Specific details on the officer involved, position affected, reason for change, or any quantitative financial metrics are NOT_DISCLOSED. Sector is not specified.
12-01-2026
Regions Financial Corp filed a Form 8-K on January 12, 2026 (AccNo: 0001281761-26-000003, Size: 271 KB) disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). The filing also includes Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No specific details on the officer involved, position affected, appointment/resignation status, reasons, or quantitative data are provided.
12-01-2026
Truist Financial Corp filed a Form 8-K on January 12, 2026 (AccNo: 0000092230-26-000006, Size: 395 KB) under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the core event, transaction value, financial impacts, or other specifics are provided in the filing summary. This appears to be a multi-item voluntary disclosure related to material nonpublic information.
12-01-2026
Evofem Biosciences, Inc. filed a Form 8-K on January 12, 2026 (AccNo: 0001493152-26-001886, Size: 14 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No details on the content of the disclosure or specific exhibits are provided. Sector is not specified.
Get daily alerts with 3 investment signals, 4 risk alerts, 3 opportunities and full AI analysis of all 37 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC